noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

ACHP - Advisory Council on[...]

San Antonio Missions National Historical Park Receives Award for[...]
Washburn University

$3 million gift establishes Robin Shrimplin Memorial Fund to support[...]
Georgia General Assembly

Reps. Davis, Scott and Schofield Support Congress’ Epstein Files[...]

Healthcare

Lake Street Capital Markets LLC

09/23/2026 | Press release | Distributed by Public on 09/23/2026 07:33

Quoin Pharmaceuticals, Ltd. (QNRX) - Initiation of Coverage

Lake Street Capital Markets Analyst, Thomas Flaten, initiated coverage of Quoin Pharmaceuticals, Ltd. with a BUY rating and price target of $20 (QNRX-$20). Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.

‍

Want to stay up-to-date with the latest at Lake Street? Subscribe to our mailing list!

NameEmail Address

Thanks for joining our mailing list.

Oops! Something went wrong while submitting the form.

Attachment

Lake Street Capital Markets LLC published this content on September 23, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 23, 2026 at 13:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format